Investigating how miRNAs modulate HER2 and HR signaling could provide critical insights into the molecular basis of tumor heterogeneity and therapy resistance, ultimately informing the development of more effective and personalized strategies for patients with HER2-low breast cancer. Here, ERBB2 is linked to breast carcinoma.